CliffBio
biologic

Kanuma

sebelipase alfa

Loss of exclusivityDecember 2027projected — 12-year biologic exclusivity estimate
CompanyAlexion Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameKanuma
Active ingredientsebelipase alfa
Strength20MG/10ML (2MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2015
Marketing statusRx

More from Alexion Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.